Vectus Biosystems has appointed Cardinal Health Regulatory Services as its US regulatory agent to manage FDA submissions for its lead fibrosis drug VB0004, marking a pivotal step towards clinical development in the US.
- Cardinal Health appointed as US FDA regulatory agent
- VB0004 targets idiopathic pulmonary fibrosis with first-in-class oral therapy
- FDA submissions include Orphan Drug Designation and IND application
- Phase Ia trial completed with favourable safety profile
- US regulatory pathway now formally established
Cardinal Health Takes Lead on US FDA Communications
Vectus Biosystems (ASX:VBS) has taken a significant step in advancing its lead compound VB0004 towards the US market by engaging Cardinal Health Regulatory Services (CHRS) as its official regulatory agent. This partnership positions CHRS as the primary liaison for all FDA-facing regulatory activities, including key submissions and communications.
CHRS will handle critical regulatory milestones such as the Orphan Drug Designation request, pre-Investigational New Drug (pre-IND) discussions, and the Investigational New Drug (IND) application for VB0004, which targets idiopathic pulmonary fibrosis (IPF). This formal engagement effectively establishes Vectus’ US regulatory pathway, a crucial foundation for further clinical development.
VB0004 Advances as a First-in-Class Oral Therapy for IPF
VB0004 is a first-in-class oral Natriuretic Peptide Receptor C agonist designed to treat IPF, a progressive and often fatal lung disease with limited treatment options. Vectus has already completed a Phase Ia clinical trial in healthy volunteers, demonstrating a favourable safety and pharmacokinetic profile. This trial outcome supports the company’s regulatory submissions and future clinical plans in the US.
Dr Tara Speranza, Vectus’ CEO and CTO, emphasised the importance of the CHRS appointment, highlighting its extensive experience in FDA regulatory strategy as a key asset in preparing for the US development programme. The company views this as a crucial step in its mission to bring a novel oral therapy to patients with significant unmet medical needs.
Broader Pipeline and Strategic Focus
While VB0004 remains the flagship asset, Vectus is concurrently advancing a broader antifibrotic pipeline targeting cardiovascular, renal, and liver fibrosis. The company’s platform approach has attracted external validation, including a licensing deal for a renal fibrosis asset, which demonstrates a pathway for future milestone and royalty revenues.
Recent capital raising efforts have supported the acceleration of VB0004’s clinical trials and other pipeline developments, underscoring Vectus’ commitment to progressing its clinical-stage assets despite ongoing funding challenges. The engagement of CHRS complements these efforts by solidifying the regulatory framework necessary for US clinical trial initiation and eventual market entry.
Bottom Line?
Vectus’ formal US regulatory engagement with Cardinal Health marks a tangible advance in its clinical development journey for VB0004, setting the stage for upcoming FDA interactions and potential trial launches.
Questions in the middle?
- How quickly will Vectus progress through FDA regulatory milestones following CHRS engagement?
- What timelines can be expected for the IND application and subsequent clinical trials in the US?
- How will the US regulatory pathway influence Vectus’ broader commercial and partnership strategy?